AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Jones, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, G.
Agricola
Right arrow Articles by Jones, G.
American Journal of Clinical Nutrition, Vol. 88, No. 2, 582S-586S, August 2008
© 2008 American Society for Nutrition


Vitamin D and Health in the 21st Century: an Update

Pharmacokinetics of vitamin D toxicity1,2,3,4

Glenville Jones

1 From the Departments of Biochemistry and Medicine, Queen's University, Kingston, Ontario, Canada

ABSTRACT

Although researchers first identified the fat-soluble vitamin cholecalciferol almost a century ago and studies have now largely elucidated the transcriptional mechanism of action of its hormonal form, 1{alpha},25-dihydroxyvitamin D3 [1{alpha},25(OH)2D3], we know surprisingly little about mechanisms of vitamin D toxicity. The lipophilic nature of vitamin D explains its adipose tissue distribution and its slow turnover in the body (half-life {approx}2 mo). Its main transported metabolite, 25-hydroxyvitamin D3 [25(OH)D3], shows a half-life of {approx}15 d and circulates at a concentration of 25–200 nmol/L, whereas the hormone 1{alpha},25(OH)2D3 has a half-life of {approx}15 h. Animal experiments involving vitamin D3 intoxication have established that 25(OH)D3 can reach concentrations up to 2.5 µmol/L, at which it is accompanied by hypercalcemia and other pathological sequelae resulting from a high Ca/PO4 product. The rise in 25(OH)D3 is accompanied by elevations of its precursor, vitamin D3, as well as by rises in many of its dihydroxy- metabolites [24,25(OH)2D3; 25,26(OH)2D3; and 25(OH)D3-26,23-lactone] but not 1{alpha},25(OH)2D3. Early assumptions that 1{alpha},25(OH)2D3 might cause hypercalcemia in vitamin D toxicity have been replaced by the theories that 25(OH)D3 at pharmacologic concentrations can overcome vitamin D receptor affinity disadvantages to directly stimulate transcription or that total vitamin D metabolite concentrations displace 1{alpha},25(OH)2D from vitamin D binding, increasing its free concentration and thus increasing gene transcription. Occasional anecdotal reports from humans intoxicated with vitamin D appear to support the latter mechanism. Although current data support the viewpoint that the biomarker plasma 25(OH)D concentration must rise above 750 nmol/L to produce vitamin D toxicity, the more prudent upper limit of 250 nmol/L might be retained to ensure a wide safety margin.




This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
P. M Brannon, E. A Yetley, R. L Bailey, and M. F. Picciano
Overview of the conference "Vitamin D and Health in the 21st Century: an Update"
Am. J. Clinical Nutrition, August 1, 2008; 88(2): 483S - 490S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The American Society for Nutrition